Avalyn Pharma Inc
AVLNHealthcare|Biotechnology|USA
$28.05
-0.94 (-3.24%)
Upcoming Data Readouts (3)
Dec 2026
Est. completion
P2Idiopathic Pulmonary Fibrosis (IPF)
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
NCT07194382n=160
Jun 2027
Est. completion
P2Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401n=375
Dec 2031
Est. completion
P2Progressive Pulmonary Fibrosis
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217n=340